论文部分内容阅读
目的:研究T淋巴细胞嗜银蛋白与妇科恶性肿瘤的相关性及在妇科恶性肿瘤中的临床应用价值。方法:利用KL型免疫分析系统检测恶性肿瘤患者398例、良性肿瘤患者254例、健康体检者100例外周血T淋巴细胞核仁形成区嗜银蛋白(Ag-NORs)含量,以银染面积与细胞核面积比值(I.S%)作为Ag-NORs检测指标。结果:恶性肿瘤患者与良性肿瘤患者及正常体检者比较外周血T淋巴细胞Ag-NORs结果差异有统计学意义(P<0.01),良性肿瘤患者与正常体检者外周血T淋巴细胞Ag-NORs结果差异无统计学意义(P>0.05)。不同组织学类型恶性肿瘤外周血T淋巴细胞Ag-NORs结果差异无统计学意义(P>0.05)。宫颈鳞状细胞癌、子宫内膜腺癌、卵巢上皮细胞癌外周血T淋巴细胞Ag-NORsI.S%<6%的分别为66%、61%、42%,低于文献报道的其他恶性肿瘤中75%～90%的I.S%值<6%,滋养细胞恶性肿瘤T淋巴细胞Ag-NORsI.S%<6%为72%,接近文献报道的值。结论:癌症的进展与T淋巴细胞rDNA转录活性的减弱相关联。人外周血T淋巴细胞Ag-NORs的检测可作为肿瘤辅助诊断的一种新指标,有助于良性疾病与恶性肿瘤之间的鉴别诊断,用于肿瘤的预后及疗效判断及合理应用免疫调节剂会有一定参考价值。
Objective: To study the correlation between T lymphocyte argyrophilic protein and gynecological malignancies and its clinical value in gynecologic malignancies. Methods: The quantity of Ag-NORs in 398 cases of malignant tumor, 254 cases of benign tumor and 100 cases of healthy volunteers were detected by KL immunoassay. Area ratio (IS%) as Ag-NORs detection index. Results: The results of Ag-NORs in peripheral blood T lymphocytes were significantly different between patients with malignant tumors and those with benign tumors and normal controls (P <0.01). The results of Ag-NORs in peripheral blood T lymphocytes of patients with benign tumors and normal controls The difference was not statistically significant (P> 0.05). The results of Ag-NORs in peripheral blood T lymphocytes of different histological types had no significant difference (P> 0.05). Cervical squamous cell carcinoma, endometrial adenocarcinoma, ovarian epithelial cell carcinoma peripheral blood T lymphocytes Ag-NORsI.S% <6% were 66%, 61%, 42%, lower than other reported malignant tumors 75% to 90% of the IS% value of <6%, T-cell lymphoma of trophoblastic tumor Ag-NORsI.S% <6% was 72%, close to the value reported in the literature. Conclusion: The progression of cancer is associated with a decrease in rDNA transcriptional activity of T lymphocytes. The detection of Ag-NORs in human peripheral blood T lymphocytes can be used as a new indicator of tumor-assisted diagnosis, which is helpful for the differential diagnosis between benign diseases and malignant tumors, for the prognosis and curative effect of tumors and the rational use of immunomodulators There will be some reference value.